Molecular profiling and commercial predication assays in ovarian cancer: still not ready for prime time?

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• Accurate ovarian cancer diagnosis and personalized treatment selection are critical for improving patient outcomes.
• In vitro chemoresponse assays have been used for decades but lack level one evidence for clinical application.
• Emerging molecular profiling assays offer insights but require rigorous scientific validation.

Purpose of the Study:

• To evaluate the current status and readiness of chemoresponse assays and molecular profiling for clinical use in ovarian cancer.
• To discuss the role of molecular patterns in improving ovarian cancer diagnosis and guiding therapy.
• To assess the predictive value of genetic mutations, such as BRCA1/2, for targeted therapies.

Main Methods:

• Review of existing literature and clinical experience with in vitro chemoresponse testing.
• Analysis of the contribution of molecular profiling to understanding ovarian cancer subtypes.
• Examination of the evidence supporting the use of specific molecular markers (e.g., BRCA mutations) for treatment selection.

Main Results:

• Neither chemoresponse assays nor molecular profiling have demonstrated sufficient clinical utility or evidence for routine application in ovarian cancer treatment.
• Molecular profiling has advanced the understanding of ovarian cancer biology and subtype-specific patterns.
• BRCA1/2 mutations show predictive value for poly(ADP-ribose) polymerase inhibitor response, but few other druggable targets have been identified.

Conclusions:

• Chemoresponse assays and molecular profiling are not yet ready for widespread clinical adoption in ovarian cancer management.
• Continued use as research tools is encouraged, with a strong emphasis on clinical trial validation.
• Further research is needed to identify reliable molecular targets and validate predictive biomarkers for personalized ovarian cancer therapy.